Literature DB >> 11316792

Analysis of the transcriptional program induced by Raf in epithelial cells.

A Schulze1, K Lehmann, H B Jefferies, M McMahon, J Downward.   

Abstract

Activation of the Raf/MAP kinase pathway is a critical event in tumorigenesis induced by RAS and other oncogenes, a major role of this signaling system being the regulation of cellular transcription factors. To address the contribution of MAP kinase mediated transcriptional changes to the transformed phenotype, we used an inducible form of Raf to analyze early changes in the transcription of some 6000 genes following activation of the kinase in a normal human breast epithelial cell line. Of the more than 120 significant changes in mRNA level detected, genes promoting cell proliferation, invasiveness, and angiogenesis featured prominently. Some of the most strongly induced genes encoded growth factors of the EGF family: Autocrine activation of the EGF receptor was shown to be responsible for the ability of Raf activation to protect these cells from apoptosis induced by detachment of cells from extracellular matrix (anoikis), which is a critical component of the transformed phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316792      PMCID: PMC312671          DOI: 10.1101/gad.191101

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  47 in total

Review 1.  Cellular survival: a play in three Akts.

Authors:  S R Datta; A Brunet; M E Greenberg
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

2.  A genome-wide survey of RAS transformation targets.

Authors:  J Zuber; O I Tchernitsa; B Hinzmann; A C Schmitz; M Grips; M Hellriegel; C Sers; A Rosenthal; R Schäfer
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

Review 3.  Extrinsic regulators of epithelial tumor progression: metalloproteinases.

Authors:  G Bergers; L M Coussens
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

Review 4.  The hemostatic system as a regulator of angiogenesis.

Authors:  T Browder; J Folkman; S Pirie-Shepherd
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

5.  Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis.

Authors:  M Rytömaa; L M Martins; J Downward
Journal:  Curr Biol       Date:  1999-09-23       Impact factor: 10.834

6.  p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway.

Authors:  Y Tan; H Ruan; M R Demeter; M J Comb
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

7.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

Authors:  A Bonni; A Brunet; A E West; S R Datta; M A Takasu; M E Greenberg
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

8.  Rsk1 mediates a MEK-MAP kinase cell survival signal.

Authors:  A Shimamura; B A Ballif; S A Richards; J Blenis
Journal:  Curr Biol       Date:  2000-02-10       Impact factor: 10.834

9.  Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F.

Authors:  J Huang; J D Hardy; Y Sun; J E Shively
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

10.  Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase.

Authors:  H Kazama; S Yonehara
Journal:  J Cell Biol       Date:  2000-02-07       Impact factor: 10.539

View more
  82 in total

1.  Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.

Authors:  Janiel M Shields; Heena Mehta; Kevin Pruitt; Channing J Der
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop.

Authors:  Pat P Ongusaha; Jong-il Kim; Li Fang; Tai W Wong; George D Yancopoulos; Stuart A Aaronson; Sam W Lee
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

3.  Walking pathways at Heidelberg. Conference on oncogenes and growth control.

Authors:  Xose R Bustelo; Piero Crespo
Journal:  EMBO Rep       Date:  2002-11       Impact factor: 8.807

4.  Prediction and measurement of an autoregulatory genetic module.

Authors:  Farren J Isaacs; Jeff Hasty; Charles R Cantor; J J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

5.  Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1.

Authors:  Brian M Iritani; Jeffrey Delrow; Carla Grandori; Ivan Gomez; Meredith Klacking; Leni Sue Carlos; Robert N Eisenman
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

6.  Making cellular memories.

Authors:  Devin R Burrill; Pamela A Silver
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

Review 7.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

Review 8.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

9.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Authors:  Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2018-08-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.